Article
BioMarin taps AI upstart Deep Genomics for discovery pact; Praxis says it has a path to lifting cli
Rating:
0.0
Views:
60
Likes:
1
Library:
1
Years after double FDA/EMA rejections left BioMarin's oligonucleotide for Duchenne muscular dystrophy languishing on the shelf, the company is going back to the drawing board for new oligonucleotide drug candidates — with a healthy dose of artificial intelligence. Its partner of choice is Deep Genomics, a Toronto-based shop led by
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value